Napier Financial’s IGC Pharma IGC Stock Holding History

Napier Financial’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16	Hold	58	–	–	﹤0.01%	467
2026 Q1	$15	Buy	+58	New	+$16	﹤0.01%	606

Other funds holding IGC

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Lawood & Co Williamsport, Pennsylvania $148M AUM

Napier Financial's IGC Position: Q2 2026 in Review

Napier Financial held its IGC Pharma (IGC) position steady in Q2 2026 at 58 shares worth $16. The position accounts for ﹤0.01% of the portfolio, ranked #467.

Napier Financial first reported a position in IGC in Q1 2026 and has held it in 2 quarters since. 36 funds tracked by Wall St. Rank hold IGC as of Q2 2026.

Napier Financial held 58 shares of IGC Pharma worth $16 as of Q2 2026.
Napier Financial left its IGC Pharma share count unchanged in Q2 2026.
IGC Pharma made up ﹤0.01% of Napier Financial's portfolio in Q2 2026, its #467 holding.
Napier Financial first reported a position in IGC Pharma in Q1 2026 and has held it in 2 quarters since.
36 funds tracked by Wall St. Rank held IGC Pharma as of Q2 2026.

Based on Napier Financial's 13F filing for Q2 2026, filed 31 Jul 2026.